A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab

NCT ID: NCT06042049

Last Updated: 2025-05-14

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 33 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-07-27
• Study Completion Date: 2025-08-15

Brief Summary

The purpose of this study is to measure the safety, PK, occurrence of ADA to nirsevimab, and anti-RSV neutralizing Ab in Japanese children with certain health conditions or pre-term infants aged ≤12 months.

Study details include

• The study duration is approximately 21 months with a 2-month enrollment period.
• Study intervention is 2 doses administered 5- 6 months apart.
• The study has 5 or 6 site visits and several telephone contacts with a 2 or 4 week interval.

Conditions

Respiratory Syncytial Virus Infections

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

MEDI8897

Anti-RSV monoclonal antibody

Group Type: EXPERIMENTAL

Nirsevimab

Intervention Type: DRUG

Participants in the first year of life will receive the 1st dose of nirsevimab as a single, fixed intramuscular (IM) dose of 50 mg if body weight is \<5 kg or 100 mg if body weight is ≥5 kg. A 2nd fixed IM dose of 50 mg if body weight is \<5 kg or 100 mg if body weight is ≥5 kg will be administered 5 to 6 months following the 1st dose.

Interventions

Nirsevimab

Participants in the first year of life will receive the 1st dose of nirsevimab as a single, fixed intramuscular (IM) dose of 50 mg if body weight is \<5 kg or 100 mg if body weight is ≥5 kg. A 2nd fixed IM dose of 50 mg if body weight is \<5 kg or 100 mg if body weight is ≥5 kg will be administered 5 to 6 months following the 1st dose.

Intervention Type: DRUG

Other Intervention Names

MEDI8897

Eligibility Criteria

Inclusion Criteria

1. Written informed consent and any locally required authorization obtained from the participant's parent(s)/legally authorized representative(s) before performing any protocol-related procedures, including screening evaluations

2. Japanese infants of ≤12 months of age eligible to receive palivizumab in accordance with national or local guidelines and those who must meet at least one of the following conditions at the time of informed consent.

1. Immunodeficiency

2. Chronic Lung Disease

3. Congenital Heart Disease

4. Down syndrome

5. Born pre-term ≤28 wks Gestation age and aged ≤12 months, or born pre-term >28 wks and ≤35 wks Gestation age and aged ≤6 months

3. The participant's parent(s)/legally authorized representative(s) can understand and comply with the requirements of the protocol including follow-up visits as judged by the investigator.

4. The participant is available to complete the follow-up period for approximately 19 months, which will be approximately 1 year after receipt of 2nd dose of nirsevimab

Exclusion Criteria

1. Requirement for mechanical ventilation, extracorporeal membrane oxygenation, continuous positive airway pressure (CPAP), or other mechanical respiratory or cardiac support at the time of enrollment

2. A current, active RSV infection at the time of screening and investigational product administration

3. Any fever (≥100.4°F [≥38.0°C], regardless of route) or acute illness at the time of prior to investigational product administration

4. Any serious concurrent medical condition (except those resulting in an immune deficiency condition), including:

1. Known renal impairment

2. Known hepatic dysfunction including known or suspected active or chronic hepatitis infection

3. Any seizure disorder or evolving or unstable neurological condition

5. Anticipated cardiac surgery within 5-6 months after enrollment

6. Prior history of a suspected or actual acute life-threatening event

7. Receipt or intended use of palivizumab in the current enrollment season

8. Any known allergy or history of allergic reaction to any component of nirsevimab

9. Any known allergy or history of allergic reaction to immunoglobulin products, blood products, or other foreign proteins

10. Concurrent enrollment in another interventional study, or prior receipt of any investigational agent

11. Anticipated survival of less than 1 year at the time of informed consent

12. Any condition that, in the opinion of the investigator, would interfere with the evaluation of the investigational product or interpretation of study results

13. Children of employees of the Sponsor, clinical study site, or any other individuals involved with the conduct of the study, or immediate family members of such individuals

• Minimum Eligible Age: 0 Years
• Maximum Eligible Age: 1 Year
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Iqvia Pty Ltd

INDUSTRY

Sponsor Role: collaborator

AstraZeneca

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Research Site

Bunkyō City, , Japan

Research Site

Fuchu-shi, , Japan

Research Site

Fukuoka, , Japan

Research Site

Kitakyusyu-shi, , Japan

Research Site

Kōtoku, , Japan

Research Site

Kurume-shi, , Japan

Research Site

Nagasaki, , Japan

Research Site

Saitama-shi, , Japan

Research Site

Yokohama, , Japan

Countries

Japan

Other Identifiers

2025-000021-13

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

D5290C00009

Identifier Type: -

Identifier Source: org_study_id